Quotables
"Fooling around with alternating current is just a waste of time. Nobody will use it, ever."
Thomas Edison ; 1889
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20120003277 | NANOEMULSION VACCINES The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides nanoemulsion compositions harboring one or more immunogens within the oil phase of the nanoemulsion and methods of using the sam... | 01/05/2012 |
| 20110311587 | Fusogenic virus-like particles and uses thereof Provided herein are novel Paramyxovirus virus-like particles, wherein said virus-like particles are composed of surface glycoprotein G; surface glycoprotein F; and matrix protein M. Further provided is a vaccine comprising the virus-like particles described herein and a... | 12/22/2011 |
| 20110305727 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F protei... | 12/15/2011 |
| 20110300180 | PLANT-DERIVED VACCINES AGAINST RESPIRATORY SYNCYTIAL VIRUS A plant-derived vaccine against respiratory syncytial virus (RSV) is disclosed. The vaccine includes an immunogenic complex that includes plant cells transformed with a chimeric gene containing a nucleotide sequence adapted for protein expression in plants and an RSV co... | 12/08/2011 |
| 20110293723 | SYNTHETIC NANOCARRIER COMBINATION VACCINES Disclosed are dosage forms and related methods, that include a first population of synthetic nanocarriers that have one or more first antigens coupled to them, one or more second antigens that are not coupled to the synthetic nanocarriers, and a pharmaceutically accepta... | 12/01/2011 |
| 20110262483 | METHODS FOR ISOLATING ENVELOPED VIRUS-BASED VLPS FREE OF INFECTIOUS AGENTS Enveloped virus-based virus-like particles (VLPs) that are free of infectious agents and substantially as immunogenic as corresponding VLPs prior to inactivation of infectious agents are described. Improved methods of inactivation infectious agents in preparations of en... | 10/27/2011 |
| 20110250267 | USE OF DIINDOLYLMETHANE-RELATED INDOLES FOR THE TREATMENT AND PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS ASSOCIATED CONDITIONS The present invention includes compositions and methods for the treatment and prevention of conditions associated with Respiratory Syncytial Virus (RSV) infection. RSV-associated conditions include acute infections in mammals, typically bronchiolitis and pneumonia, and ... | 10/13/2011 |
| 20110223197 | Mucosal and Systemic Immunization with Alphavirus Replicon Particles Mucosal and systemic administration of compositions comprising alphavirus replicon particles to induce immune responses in a subject is described.... | 09/15/2011 |
| 20110223195 | COMPOSITION COMPRISING CHITOSAN FOR OCULAR ADMINISTRATION OF VACCINE(S) TO AVIANS The invention relates to vaccine compositions comprising chitosan and a vaccine which are administered to avian species via the ocular route, and methods or programs of vaccination including use of chitosan in order to increase or enhance cell-mediated immunity in avian... | 09/15/2011 |
| 20110212123 | Immunogenic Substances Comprising a Polyinosinic Acid - Polycytidilic Acid Based Adjuvant The present invention provides a polynucleotide adjuvant (PICKCa) composition and methods of use in eliciting an immune response, in particular a mucosal immune response. The polynucleotide adjuvant comprises of a polyriboinosinic-polyribocytidylic acid (PIC), at least ... | 09/01/2011 |
| 20110212130 | LIVE, ATTENUATED RESPIRATORY SYNCYTIAL VIRUS The present invention features live, attenuated respiratory syncytial viruses (RSV) useful as vaccines against RSV infection and/or the development of severe RSV-associated illnesses. The disclosed viruses are attenuated to the extent of being nonpathogenic when adminis... | 09/01/2011 |
| 20110189232 | RECOMBINANT HUMAN PARAINFLUENZA TYPE 1 VIRUSES (HPIV1s) CONTAINING MUTATIONS IN OR DELETION OF THE C PROTEIN ARE ATTENUATED IN AFRICAN GREEN MONKEYS AND IN CILIATED HUMAN AIRWAY EPITHELIAL CELLS AND ARE POTENTIAL VACCINE CANDIDATES FOR HPIV1 Two recently characterized live attenuated HPIV1 vaccine candidates, rHPIV1-CR84G/Δ170HNT553ALY942A and rHPIV1-CR84G/Δ170HN-T553ALΔ1710-11, which contain temperature sensitive (ts) attenuating (att) an... | 08/04/2011 |
| 20110177117 | CHIMERIC RESPIRATORY SYNCYTIAL VIRUS POLYPEPTIDE ANTIGENS Chimeric respiratory syncytial virus (RSV) polypeptide antigens are provided. The disclosed polypeptides include a first amino acid sequence comprising an F2 domain uncleavably joined to an F1 domain of a Respiratory Syncytial Virus (RSV) Fusion (F) protein polypeptide;... | 07/21/2011 |
| 20110150940 | DRY POWDER COMPOSITIONS AND SYSTEMS FOR POULTRY VACCINATION This invention provides a dry powder composition for poultry vaccination via inhalation comprising an effective amount of a poultry vaccine agent, and a supporting amount of carriers for said poultry vaccine agent, said carriers comprising a combination of a reducing or... | 06/23/2011 |
| 20110142912 | NON-SPECIFIC IMMUNOSTIMULATING AGENTS The present invention relates to the use of a lipid vesicle for the preparation of a medicament. The invention further relates to a method of treating and/or preventing a disease or disorder involving administering such a lipid vesicle to an animal in need thereof.... | 06/16/2011 |
| 20110097358 | RESPIRATORY SYNCYTIAL VIRUS (RSV) VIRUS-LIKE PARTICLES (VLPs) Respiratory syncytial virus (RSV) virus-like particles (VLPs) comprising at least one RSV protein are described. Also described are compositions comprising these VLPs as well as methods of making and using these VLPs.... | 04/28/2011 |
| 20110091496 | METHODS AND COMPOSITIONS FOR THE DELIVERY OF VACCINES TO DISRUPTED EPITHELIUM The invention features immunogenic compositions and methods useful for eliciting an immune response. In preferred embodiments, papillomavirus or adenovirus vectors are used to elicit exceptionally potent antibody and T cells responses in disrupted epithelium. The method... | 04/21/2011 |
| 20110081378 | COMPOSITION COMPRISING ISCOM PARTICLES AND LIVE MICRO-ORGANISMS Iscom particles can be used as an adjuvant for preparing of an antigenic composition which comprises live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A composition may comprise at least one iscom particle and one or more live micro-organism... | 04/07/2011 |
| 20110070290 | VACCINE COMPOSITION CONTAINING SYNTHETIC ADJUVANT Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provide... | 03/24/2011 |
| 20110045023 | Recombinant RSV Virus Expression Systems And Vaccines The present invention relates to genetically engineered recombinant respiratory syncytial viruses and viral vectors which contain deletions of various viral accessory gene(s) either singly or in combination. In accordance with the present invention, the recombinant resp... | 02/24/2011 |
| 20100330120 | HUMAN PARAINFLUENZA VIRUSES HAVING SEPARATED P AND C GENES The invention provides self replicating infectious recombinant paramyxoviruses where the P and C genes are separated rated. The recombinant paramyxoviruses preferably have one or more attenuating mutations and/or at least one temperature sensitive mutation and one non-t... | 12/30/2010 |
| 20100316673 | NANOEMULSION VACCINES The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides immunogenic nanoemulision compositions and methods of using the same to induce immune responses (e.g., immunity (e.g., protectiv... | 12/16/2010 |
| 20100291147 | RECOMBINANT RSV ANTIGENS This disclosure provides recombinant respiratory syncytial virus (RSV) antigens and methods for making and using them, including immunogenic compositions (e.g., vaccines) for the treatment and/or prevention of RSV infection.... | 11/18/2010 |
| 20100278862 | Nipah Virus Vaccines The present invention relates to recombinant anti-Nipah virus vaccines and the administration of such vaccines to animals, advantageously pigs. Advantageously, the anti-Nipah virus vaccine may comprise a recombinant avipox virus containing a Nipah virus glycoprotein gen... | 11/04/2010 |
| 20100266629 | Cattle Reproductive Disease Vaccines The present invention relates to combination vaccines and methods for treating or preventing diseases or disorders in an animal caused by infection by Bovine Viral Diarrhea Virus (BVDV) Types 1 and 2, Bovine Herpes Virus Type-1 (BHV-1), Bovine Respiratory Syncytial Viru... | 10/21/2010 |
| 20100260796 | Stabilizers for freeze-dried vaccines The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the present invention relates to stabilizers for freeze-dried live attenuated immunogenic and/or vaccine compositions, which may comprise, inter alia, canine p... | 10/14/2010 |
| 20100247537 | ADJUVANT COMBINATIONS OF NKT ACTIVATOR, CD40 AGONIST, AND OPTIONAL ANTIGEN, THE USE THROUGH INDUCING SYNERGISTIC CELLULAR IMMUNITY Adjuvant combinations comprising at least one NKT activator, such as alpha-galactosylceramide (α-Gal-Cer) or iGb3, a CD40 agonist and optionally an antigen are disclosed. The use of these immune adjuvants for treatment of various chronic diseases such as cancers is als... | 09/30/2010 |
| 20100247571 | METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST VIRUS Immunogenic compositions comprising partially glycosylated viral glycoproteins for use as vaccines against viruses are provided. Vaccines formulated using mono-, di-, or tri-glycosylated viral surface glycoproteins and polypeptides provide potent and broad protection ag... | 09/30/2010 |
| 20100247621 | CODON MODIFIED IMMUNOGENIC COMPOSITIONS AND METHODS OF USE The present invention features immunogenic compositions comprising codon modified genes that encode viral proteins and/or glycoproteins or fragments. The immunogenic compositions of the invention are useful in various methods of treatment, such as preventing or treating... | 09/30/2010 |
| 20100239611 | Combination adjuvant formulation Methods and compositions for enhancing an immune response to a selected antigen are described. The methods are useful for the treatment and prevention of microbial infections, such as infections caused by bacteria, viruses, fungi and parasites. The methods and compositi... | 09/23/2010 |
| 20100150958 | Methods and Compositions for Use of a Coccidiosis Vaccine The invention relates to new vaccine compositions for vaccinating birds.... | 06/17/2010 |
| 20100143400 | Immunostimulatory Oligonucleotides The invention relates to immunostimulatory oligonucleotides and methods of using immunostimulatory oligonucleotides to induce an antigen-specific immune response. The invention further relates to a vaccine that comprises an immunostimulatory oligonucleotide and an antig... | 06/10/2010 |
| 20100112078 | POLYMER PARTICLES BASED VACCINE The present invention provides a vaccine composition comprising an effective amount of antigen or a nucleic acid encoding antigen, encapsulated in polymeric particles, wherein said polymeric particles comprises nanoparticles, microparticles or combinations thereof, wher... | 05/06/2010 |
| 20100111999 | PRODUCTION OF POXVIRUSES WITH ADHERENT OR NON ADHERENT AVIAN CELL LINES The present invention relates to a method for replicating poxviruses such as vaccinia virus comprising the steps of inoculating avian embryonic stem cells with viral particles and culturing said cells in a basal medium until cells lysis occurs and newly produced viral p... | 05/06/2010 |
| 20100068226 | Polynucleotides and Uses Thereof The present invention provides an isolated polynucleotide comprising or consisting of the nucleotide sequence encoding the G protein of human respiratory syncytial virus (RSV), wherein the nucleotide sequence is codon optimised for expression in mammalian cells and wher... | 03/18/2010 |
| 20100047277 | VIROSOMES, METHODS OF PREPARATION, AND IMMUNOGENIC COMPOSITIONS Briefly described, virosomes, methods of preparing virosomes, immunogenic compositions that include virosomes, and methods of eliciting an immune response using immunogenic compositions that include virosomes are described herein. A virosome can include at least one vir... | 02/25/2010 |
| 20100040650 | Virus-Like paramyxovirus particles and vaccines The present invention is directed to alphavirus virus-like particles produced by synthesizing in cell, including in vivo, structural proteins in the absence of other alphavirus proteins. In particular, these virus-like particules vaccines induce cellular and humoral imm... | 02/18/2010 |
| 20100028379 | METHODS OF VACCINE ADMINISTRATION This invention relates to a method of treating a dog for canine diseases comprising administering to the dog therapeutically effective amounts of a vaccine, wherein the vaccine comprises viral antigens, a bacterin, or both, and wherein the vaccine is administered subcut... | 02/04/2010 |
| 20100028383 | Chemically defined stabiliser The present invention relates to a stabiliser composition comprising an amino acid, and a sugar wherein all compounds are chemically defined; to a vaccine composition comprising such a stabiliser composition and a biological molecule and/or a micro-organism; to a method... | 02/04/2010 |
| 20100028377 | Recombinant RSV Virus Expression Systems And Vaccines The present invention relates to genetically engineered recombinant respiratory syncytial viruses and viral vectors which contain deletions of various viral accessory gene(s) either singly or in combination. In accordance with the present invention, the recombinant resp... | 02/04/2010 |
